Table 3 Description of PIs with a major clinical impact (n = 21)
Unit | DRP | Drug(s) | PI | Description | Economic impact | Organizational impact |
|---|---|---|---|---|---|---|
Hepato-gastro enterology day care unit | Non conformity to guidelines | Panitumumab | Drug switch | Course number 1: Prescription VECTIBIX / FOLFOX instead of AVASTIN FOLFOX (RAS analysis in progress) | 1 | 0 |
Hepato-gastro enterology day care unit | Non conformity to guidelines | Panitumumab | Drug switch | Course number 1: Prescription VECTIBIX / FOLFOX instead of AVASTIN FOLFOX (RAS analysis in progress) | 1 | 0 |
Oncology day care unit | Non conformity to guidelines | Gemcitabine | Drug discontinuation | Prescription signed and green light given for gemcitabine but course should be canceled due to thrombocytopenia | 1 | 1 |
Radiotherapy day care unit | Non conformity to guidelines | Cisplatin | Dose adjustment | Overdose: Prescription cisplatin 60 mg / m2 for 2 days, while the patient should not receive cisplatin on day 2 | 1 | 1 |
Pneumology day care unit | Contra indication | Cisplatin | Drug discontinuation | Prescription of an adjuvant cisplatin course for a patient having a clearance of creatinine 43 ml/min according to the CKD EPI formula | 1 | 1 |
Oncology day care unit | Untreated indication | Trastuzumab | Addition of a new drug | Error in the protocol: missing one line in protocol on Taxotere Cyclophosphamide Trastuzumab | 0 | 1 |
Oncology day care unit | Untreated indication | Trastuzumab | Addition of a new drug | Error in the protocol: missing one line in protocol on Taxotere Cyclophosphamide Trastuzumab | 0 | 1 |
Hepato-gastro enterology day care unit | Supra-therapeutic dosage | Fluorouracile Oxaliplatin | Dose adjustment | Reductions of 50% of in 5 fluorouracil (5FU) and of 80% in oxaliplatin omitted in a patient with toxic ileitis to 5 FU in his medical records | 1 | 0 |
Oncology day care unit | Supra-therapeutic dosage | Cetuximab | Dose adjustment | Expected reduction cetuximab 200 mg / m2 instead of 500 mg / m2 not appliedToxicity during previous treatments: folliculitis, xerosis | 1 | 1 |
Oncology day care unit | Supra-therapeutic dosage | Cyclophosphamide Doxorubicine Cisplatine | Dose adjustment | Expected reductions of 80% for Cyclophosphamide and doxorubicin and of 66% for cisplatin omitted. During the intercure period: anemia, thrombocytopenia, non-febrile agranulocytosis, oedematous decompensation leading to emergency consultation | 1 | 1 |
Oncology day care unit | Supra-therapeutic dosage | Irinotecan | Dose adjustment | Reduction of 80% for irinotecan omitted During the intercure period: Hospitalization for diarrhea during previous course | 1 | 1 |
Oncology day care unit | Supra-therapeutic dosage | Paclitaxel | Dose adjustment | Expected reduction to 80% paclitaxel not appliedToxicity: paresthesia of hands and feet prior to paclitaxel | 1 | 1 |
Oncology day care unit | Supra-therapeutic dosage | Cabazitaxel | Dose adjustment | Expected reduction to 80% for carbazitaxel Hospitalization during previous course for deterioration in general condition and nausea | 1 | 1 |
Oncology day care unit | Supra-therapeutic dosage | Paclitaxel | Dose adjustment | Expected reduction of 80% for paclitaxel omitted Toxicity: Feet paresthesia prior to paclitaxel | 1 | 1 |
Oncology day care unit | Supra-therapeutic dosage | Paclitaxel | Dose adjustment | Expected reduction of 80% paclitaxel not appliedToxicity: Hands and feet paresthesia prior to paclitaxel | 1 | 1 |
Oncology day care unit | Supra-therapeutic dosage | Paclitaxel | Dose adjustment | Expected reduction of 80% for paclitaxel not applied Toxicity during previous treatments: Neuropathy | 1 | 1 |
Oncology day care unit | Supra-therapeutic dosage | Docetaxel | Dose adjustment | Expected reduction of 66% for not applied Toxicity during intercure: Edema of the lower limbs | 1 | 1 |
Oncology day care unit | Supra-therapeutic dosage | Vinorelbine | Dose adjustment | Prescription of weekly navelbine at dosage of 25 mg / m2Medical history: Neutropenia grade IV with a weekly navelbine protocol | 1 | 1 |
Oncology day care unit | Supra-therapeutic dosage | Vinorelbine | Dose adjustment | Expected reduction of 80% for navelbine Toxicity during intercure: Hospitalization for general condition alteration and febrile peak | 1 | 1 |
Oncology day care unit | Supra-therapeutic dosage | Gemcitabine | Dose adjustment | Expected reduction of 80% for gemcitabine not applied Toxicity during previous treatment: Febrile neutropenia | 1 | 1 |
Oncology day care unit | Supra-therapeutic dosage | Cisplatin Fluorouracile | Dose adjustment | Course number 1: expected reductions because of asthenia and undernutrition by 80% for cisplatin and fluorouracile not applied | 1 | 1 |